Gynaeco
Ovarium cancer resistant or refractory
POLKA: phase II randomized trial of the Polo-like kinase 1 inhibitor BI6727 monotherapy versus investigator's choice chemotherapy in ovarian cancer patients resistant or refracory to platinum-based cytotoxic therapy.
-
Study phase II
Ovarium, advanced disease
A randomized discontinuation study of Brivanib alaninate (BMS-582664) versus Placebo in Subjets with advanced tumors.
- Study Phase II
- Selection criteria
Ovarium cancer
Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with 2 or more platinum containing regimens.
-
Study Phase II
Advanced serous ovarian cancer
A phase II, open-label, randomised, comparative, multicentre study to compare the efficacy and tolerability of oral Olaparib in combination with carboplatin and paclitaxel versus carboplatin and paclitaxel alone in patients with platinum sensitive advanced serous ovarian cancer.
- Study phase II